Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

35.30 -0.04 (-0.11%)
Official Closing Price Updated: 7:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,476,081
Open 35.33
Bid (Size) 35.11 (1)
Ask (Size) 35.59 (1)
Prev. Close 35.34
Today's Range 35.12 - 35.44
52wk Range 28.46 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
How Could GSK's RSV Vaccine Change its Valuation?
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future. 
Via MarketBeat
Exposures Product Safety
Earnings Preview: GSK Q4 Earnings Expected To Decline
This drug developer is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -31.4%. 
Via Talk Markets

Performance

YTD
+0.03%
+0.03%
1 Month
+0.48%
+0.48%
3 Month
+6.42%
+6.42%
6 Month
-15.21%
-15.21%
1 Year
-21.99%
-21.99%

More News

Read More
3 Penny Stocks That Could Make You Filthy Rich
Via The Motley Fool
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Via Benzinga
GSK Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock
Via The Motley Fool
Stock Market Rally Pulls Back; Microsoft, Google Slash Jobs; Netflix, Goldman, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
Via Investor's Business Daily
Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy'
Via Benzinga
Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today
Via Benzinga
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up
Via Investor's Business Daily
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact
Via Talk Markets
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines
Via InvestorPlace
The Year of the Tripledemic
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death Product Safety
The Year of the Tripledemic
Via News Direct
Topics Death
Exposures COVID-19 Death
What You Missed On Wall Street On Friday
Via Talk Markets
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
Via Benzinga
Big Health Care Stocks to Watch in the New Year
Via MarketBeat
7 Drug Stocks That Will Soar in 2023
Via InvestorPlace
2 Smartest Tech Stocks to Buy in 2022 and Beyond
Via The Motley Fool
Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says
Via Benzinga
Options Trader Betting On GSK Stock Rising Heading Into 2023
Via Benzinga
Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders
Via Benzinga
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
From Wave Life Sciences USA, Inc.
Via Globe NewsWire
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
From GSK plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.